Welcome to our dedicated page for CalciMedica SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CalciMedica, Inc. filings document regulatory disclosures for a clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies. The company’s Form 8-K reports cover results of operations and financial condition, clinical program events involving Auxora, and related updates for inflammatory and immunologic disease programs.
The filing record also includes capital-structure and governance disclosures, including Nasdaq continued-listing compliance matters, at-the-market offering documentation, shareholder voting matters, and the company’s common stock registration on The Nasdaq Capital Market under the symbol CALC.
CalciMedica, Inc. director and chief executive officer Rachel A. Leheny received a grant of 148,482 employee stock options to buy common stock at an exercise price of $0.585 per share. The options expire on April 4, 2036.
Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years. No shares will vest until a Form S-8 is filed for shares automatically added to the company’s 2023 Equity Incentive Plan on January 1, 2026.
CalciMedica, Inc. reported that Nasdaq has notified the company it no longer meets multiple continued listing standards for the Nasdaq Capital Market. The market value of its listed securities has stayed below the $35,000,000 minimum for 30 consecutive business days, triggering a 180-day cure period ending on September 9, 2026.
The company can regain compliance by meeting any of the alternatives: stockholders’ equity of at least $2,500,000, market value of listed securities of at least $35,000,000, or net income from continuing operations of $500,000 in the relevant periods. Separately, Nasdaq also notified CalciMedica that its common stock has traded below the $1.00 minimum bid price for 30 consecutive business days, starting another 180-day grace period through September 14, 2026 to restore the bid price for at least 10 consecutive business days.
The stock continues to trade on Nasdaq under the symbol CALC, but failure to regain compliance could lead to delisting. The company plans to monitor the requirements and is considering options such as a reverse stock split, while noting there is no assurance it will successfully regain or maintain compliance.
CalciMedica, Inc. has filed a shelf registration prospectus to offer, from time to time, up to $125,000,000 of common stock, preferred stock, debt securities and/or warrants.
The filing states offerings will be made in one or more offerings with specific terms provided in prospectus supplements; sales are described as issuer offerings and proceeds are for the issuer’s general corporate purposes. The company’s common stock trades on Nasdaq under the symbol CALC (last reported sale $0.507 per share on March 2, 2026).
CalciMedica, Inc. is a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibitors, led by its intravenous candidate Auxora for acute pancreatitis and other critical inflammatory conditions. The company has never generated product revenue and discloses a history of net losses with substantial doubt about its ability to continue as a going concern without significant additional capital.
Auxora has shown encouraging Phase 2 data in acute pancreatitis, severe COVID-19 pneumonia, and pediatric asparaginase-induced pancreatic toxicity, and CalciMedica plans to finalize a pivotal program design in acute pancreatitis in the first half of 2026. A Phase 2 trial in acute kidney injury with acute hypoxemic respiratory failure (KOURAGE) was discontinued in January 2026 after a mortality imbalance, though independent reviewers did not find drug-related toxicity, and the company will discuss future development with the FDA.
CalciMedica is also advancing CM5480, an Orai1-selective CRAC inhibitor, toward an anticipated 2027 IND for pulmonary arterial hypertension and is exploring oral CRAC inhibitors in chronic inflammatory and immunologic diseases. It relies on third-party manufacturers, faces intense competition in inflammation and critical care, and highlights extensive scientific and development risks alongside potential opportunities for strategic partnerships.
CalciMedica Inc. reported a full-year 2025 net loss of $29.6 million, or $1.97 per share, compared with a net loss of $13.7 million in 2024. Research and development spending rose to $15.2 million, while general and administrative expenses fell to $7.9 million.
Cash, cash equivalents and short-term investments totaled $13.0 million as of December 31, 2025, which the company expects will fund its current operating plan into the fourth quarter of 2026. Liabilities increased, including a promissory note and a higher warrant liability, leading to a stockholders’ deficit.
Clinically, the company reported no evidence of drug-related toxicity from the unblinded Phase 2 KOURAGE AKI trial, despite a previously disclosed mortality imbalance and trial discontinuation. Auxora is being advanced toward a pivotal acute pancreatitis program, with design expected to be finalized in the first half of 2026, and CM5480 continues preclinical development for pulmonary arterial hypertension with an IND submission anticipated in 2027.
CalciMedica Inc. (CALC) received an amended Schedule 13G from investment entities affiliated with Deerfield and James E. Flynn. The filing reports beneficial ownership of 653,253 shares of common stock, all issuable upon exercise of warrants held by Deerfield Partners, L.P.
The position represents 4.34% of CalciMedica’s common stock. All reporting persons disclose zero sole voting or dispositive power and shared voting and dispositive power over the same 653,253 shares. They also certify the holdings were not acquired to change or influence control of CalciMedica, characterizing the stake as passive.
CalciMedica, Inc. reported that it has discontinued its Phase 2 KOURAGE clinical trial after a recommendation from the study’s Independent Data Monitoring Committee. The company cited reduced planned operating expenses from stopping the trial and updated its cash outlook accordingly.
CalciMedica now expects its existing cash, cash equivalents and short-term investments to fund its current operating plan into the fourth quarter of 2026, an improvement from its prior guidance of funding into the second half of 2026. The company also reiterated standard cautionary language about forward-looking statements and referenced previously disclosed risk factors.
CalciMedica, Inc. has discontinued its Phase 2 KOURAGE clinical trial of Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure. The move follows a safety-related recommendation from the trial’s Independent Data Monitoring Committee, which believes the study design and patient enrollment criteria should be reevaluated.
The company states there were no deaths assessed as related to Auxora or placebo, and no serious adverse events triggered expedited U.S. Food and Drug Administration reporting. CalciMedica will conduct a comprehensive review of the unblinded data to understand how baseline characteristics, disease severity and concomitant therapies influenced outcomes and to determine how future clinical evaluation of Auxora in AKI may proceed. The FDA has been notified, and investigators will follow all enrolled patients for 90 days.
CalciMedica, Inc. filed its Q3 2025 report, detailing ongoing operating losses and liquidity pressure. The company reported a net loss of $7.804 million for the quarter and $18.802 million for the nine months ended September 30, 2025. Operating expenses were $5.618 million in Q3, led by research and development of $3.851 million.
As of September 30, 2025, cash and cash equivalents were $5.470 million and short‑term investments were $8.614 million. Management states there is substantial doubt about the company’s ability to continue as a going concern. The balance sheet shows a stockholders’ deficit of $268 thousand, a promissory note at fair value of $8.900 million, and a warrant liability of $2.600 million.
The company funded $10.0 million under a loan on February 28, 2025, bearing interest at the greater of 5.00% + prime or 12.75%, maturing on September 1, 2028. During 2025, it raised additional equity via its ATM program, selling 760,130 shares for net proceeds of $1.761 million through September 30. Shares outstanding were 14,409,431 as of November 6, 2025.